Hey All,
Clarity 1 results are out. In mild disease with COVID-19 & this was with ARB only, not DMX-200 on top of ARB. So it’s not our trial (Clarity 2.0). Need to read for context.
https://www.bmj.com/content/379/bmj-2022-072175
But as I suspected earlier on, large platform trials such as REMAP CAP & others with NHMRC already involved with, will collaborate on data collected as per WHO standards, which I also suspect will happen with DMX-200 data in hospitalised patients (moderate-severe state). Need to look at demographics of recruitment & all this paper. I’m not put off by this at all in ARB alone in mildly sick patients. No wonder the criteria was changed to hospitalised & requiring O2 for Clarity 2.
Now to look at DXB latest presentation, sounds positive. Thanks for the posts Guys!
Hey All, Clarity 1 results are out. In mild disease with...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
44.5¢ |
Change
-0.010(2.20%) |
Mkt cap ! $247.9M | |||
| Open | High | Low | Value | Volume |
| 45.0¢ | 45.8¢ | 43.8¢ | $701.3K | 1.564M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 111371 | 44.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 45.0¢ | 8072 | 1 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| DXB (ASX) Chart |